UB Paderborn / Katalog / Suche / in CDI

Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA

The New England journal of medicine, 2020-07, Vol.383 (3), p.207-217

2020

Volltextzugriff (PDF)

Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial

Lancet neurology, 2017-04, Vol.16 (4), p.301-310

2017

Volltextzugriff (PDF)

Serum c-reactive protein concentration and genotype in relation to ischemic stroke subtype

Stroke (1970), 2006-08, Vol.37 (8), p.2018-2023

2006

Volltextzugriff (PDF)

Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial

Clinical trials (London, England), 2020-12, Vol.17 (6), p.617-626

2020

Volltextzugriff (PDF)

Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source

Stroke (1970), 2017-09, Vol.48 (9), p.2480-2487

2017

Volltextzugriff (PDF)

Total intracranial hemorrhage volume measurement summating all compartments best in traumatic and nontraumatic intracranial bleeding

Brain and behavior, 2024-05, Vol.14 (5), p.e3481-n/a

2024

Volltextzugriff (PDF)

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Stroke: vascular and interventional neurology, 2024-01, Vol.4 (1)

2024

Volltextzugriff (PDF)

Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

BMJ neurology open, 2023-08, Vol.5 (2), p.e000478-e000478

2023

Volltextzugriff (PDF)

C-Reactive Protein Is a Determinant of First-Ever Stroke: Prospective Nested Case-Referent Study

Cerebrovascular diseases (Basel, Switzerland), 2009-01, Vol.27 (6), p.544-551

2009

Volltextzugriff (PDF)

Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial

Neurology, 2019-08, Vol.93 (7), p.e708

2019

Volltextzugriff (PDF)

Abstract WP126: Predictors Of Intracranial Hemorrhage Volume Expansion In Patients Receiving Factor Xa Inhibitors In The Annexa-4 Trial

Stroke (1970), 2023-02, Vol.54 (Suppl_1)

2023

Volltextzugriff (PDF)

Identification of eight novel single-nucleotide polymorphisms at human tissue-type plasminogen activator (t-PA) locus: association with vascular t-PA release in vivo

Thrombosis and haemostasis, 2000-08, Vol.84 (2), p.150

2000

Volltextzugriff (PDF)

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

Stroke (1970), 2021-11, Vol.52 (11), p.3482-3489

2021

Volltextzugriff (PDF)

Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample

International journal of cardiology, 2018-04, Vol.257, p.46-49

2018

Volltextzugriff (PDF)

Abstract MP4: Ticagrelor Plus Aspirin Versus Aspirin Alone in Acute Ischemic Stroke or TIA - Analysis of Bleeding Events in the THALES Trial

Stroke (1970), 2021-03, Vol.52 (Suppl_1)

2021

Volltextzugriff (PDF)

Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction

Thrombosis and haemostasis, 2002-01, Vol.87 (1), p.105

2002

Volltextzugriff (PDF)

The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design

International Journal of Stroke, 2019-10, Vol.14 (7), p.745-751

2019

Volltextzugriff (PDF)

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage

The New England journal of medicine, 2024-05, Vol.390 (19), p.1745

2024

Volltextzugriff (PDF)

Low aerobic capacity in middle-aged men associated with increased mortality rates during 45 years of follow-up

European journal of preventive cardiology, 2016-09, Vol.23 (14), p.1557-1564

2016

Volltextzugriff (PDF)

Patent foramen ovale can cause cryptogenic stroke. Transcatheter closure as an alternative to medical therapy must be evaluated more

Läkartidningen, 2013-09, Vol.110 (36), p.1524-1525

2013

Volltextzugriff (PDF)

Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial

Stroke (1970), 2018-07, Vol.49 (7), p.1678-1685

2018

Volltextzugriff (PDF)

Rapid genotyping of haemostatic gene polymorphisms using the 5' nuclease assay

Thrombosis and haemostasis, 2003-05, Vol.89 (5), p.936

2003

Volltextzugriff (PDF)

Recurrent stroke in patients with patent foramen ovale: An observational prospective study of percutaneous closure of PFO versus non-closure

International journal of cardiology, 2015-09, Vol.195, p.293-299

2015

Volltextzugriff (PDF)

Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial

Stroke (1970), 2019-03, Vol.50 (3), p.675-682

2019

Volltextzugriff (PDF)

Fibrinolytic gene polymorphism and ischemic stroke

Stroke (1970), 2005-10, Vol.36 (10), p.2077-2081

2005

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA

Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial

Serum c-reactive protein concentration and genotype in relation to ischemic stroke subtype

Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial

Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source

Total intracranial hemorrhage volume measurement summating all compartments best in traumatic and nontraumatic intracranial bleeding

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

C-Reactive Protein Is a Determinant of First-Ever Stroke: Prospective Nested Case-Referent Study

Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial

Abstract WP126: Predictors Of Intracranial Hemorrhage Volume Expansion In Patients Receiving Factor Xa Inhibitors In The Annexa-4 Trial

Identification of eight novel single-nucleotide polymorphisms at human tissue-type plasminogen activator (t-PA) locus: association with vascular t-PA release in vivo

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample

Abstract MP4: Ticagrelor Plus Aspirin Versus Aspirin Alone in Acute Ischemic Stroke or TIA - Analysis of Bleeding Events in the THALES Trial

Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction

The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage

Low aerobic capacity in middle-aged men associated with increased mortality rates during 45 years of follow-up

Patent foramen ovale can cause cryptogenic stroke. Transcatheter closure as an alternative to medical therapy must be evaluated more

Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial

Rapid genotyping of haemostatic gene polymorphisms using the 5' nuclease assay

Recurrent stroke in patients with patent foramen ovale: An observational prospective study of percutaneous closure of PFO versus non-closure

Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial

Fibrinolytic gene polymorphism and ischemic stroke

Suchergebnisse filtern